Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients

https://doi.org/10.1016/S0049-3848(12)70008-7Get rights and content

Abstract

Venous thromboembolism (VTE) is a common problem in cancer patients. However, the rates of VTE vary widely between different types of malignancies. Furthermore, patient- and treatment-related risk factors contribute to the risk of VTE. The prediction of the individual risk of VTE and the identification of patients with cancer that might benefit from thromboprophylaxis is a major clinical challenge, because the pathogenesis of cancer-associated VTE is multifactorial. Therefore, recent studies have focused on identification of predictive biomarkers for VTE. As there is a close interrelation between cancer and the haemostatic system, which leads to activation of haemostasis and fibrinolysis, biomarkers of the haemostatic system seem to be promising in predicting risk of developing VTE in cancer patients. Some candidate biomarkers or laboratory tests of the haemostatic system including platelet count, soluble P-selectin, tissue factor (TF) and TF-bearing microparticles, coagulation factor VIII, D-dimer, prothrombin fragment 1+2 and the thrombin generation assay have been reported to predict cancer-associated VTE. In addition, it has been shown that risk-scoring models, incorporating clinical parameters and biomarkers, allow risk stratification of cancer patients into groups at high- and at low risk of VTE. The accuracy of a previously established risk scoring model can be improved when it is expanded and biomarkers of the haemostatic system are added. The benefit of a targeted thromboprophylaxis for primary prevention of VTE in cancer patients based on risk assessment by measuring biomarkers or applying risk scoring models has to be shown in interventional clinical trials.

References (55)

  • C Ay et al.

    High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

    Blood

    (2008)
  • DD Myers et al.

    Decreased venous thrombosis with an oral inhibitor of P selectin

    J Vasc Surg

    (2005)
  • BA Bouchard et al.

    The participation of leukocytes in coagulant reactions

    J Thromb Haemost

    (2003)
  • I Del Conde et al.

    Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation

    Blood

    (2005)
  • R Nieuwland et al.

    Why do cells release vesicles?

    Thromb Res

    (2010)
  • ME Tesselaar et al.

    Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

    J Thromb Haemost

    (2007)
  • ME Tesselaar et al.

    Microparticle-associated tissue factor activity in cancer patients with and without thrombosis

    J Thromb Haemost

    (2009)
  • DA Manly et al.

    Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism

    Thromb Res

    (2010)
  • E Campello et al.

    Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism

    Thromb Res

    (2011)
  • AA Khorana et al.

    Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer

    J Thromb Haemost

    (2008)
  • FR Rickles et al.

    Tissue factor, thrombin, and cancer

    Chest

    (2003)
  • H Ten Cate

    Thrombin generation in clinical conditions

    Thromb Res

    (2012)
  • T Sousou et al.

    Identifying cancer patients at risk for venous thromboembolism

    Hamostaseologie

    (2009)
  • GH Lyman et al.

    Cancer, clots and consensus: new understanding of an old problem

    J Clin Oncol

    (2009)
  • AA Khorana et al.

    Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

    Cancer

    (2005)
  • P André et al.

    Pro-coagulant state resulting from high levels of soluble P-selectin in blood

    Proc Natl Acad Sci U S A

    (2000)
  • I Pabinger et al.

    Biomarkers and venous thromboembolism

    Arterioscler Thromb Vasc Biol

    (2009)
  • Cited by (0)

    View full text